NCT02809976View on ClinicalTrials.gov

Topical Ruxolitinib for the Treatment of Vitiligo

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

February 28, 2017

Conditions
Vitiligo
Interventions
DRUG

Ruxolitinib 1.5% Phosphate Cream

twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20

Trial Locations (1)

02111

Tufts Medical Center, Boston

All Listed Sponsors
lead

Tufts Medical Center

OTHER

NCT02809976 - Topical Ruxolitinib for the Treatment of Vitiligo | Biotech Hunter | Biotech Hunter